Friday, August 15, 2025 8/15/2025

Targeting PP4 to improve ovarian cancer response to immunotherapy

Award Number: R37CA276047
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/03/2023
PERIOD OF PERFORMANCE END DATE: 07/31/2028

Group Awards By:

View Award Description

Targeting PP4 to improve ovarian cancer response to immunotherapy - PROJECT SUMMARY/ABSTRACT High-grade serous ovarian cancer has the highest mortality rate of all gynecologic cancers. There is a critical unmet need to identify new therapeutic targets and therapeutic approaches that will improve outcomes for women with chemo-resistant ovarian cancer. Deficiencies in the DNA damage response (DDR) can drive increased tumor immunogenicity, which leads to enhanced responses to immune checkpoint inhibitor therapy. PP4 is a multi-subunit phosphatase complex that plays a central role in the response to DNA damage through the dephosphorylation of many proteins that play crucial roles in the DDR. However, the role of PP4 in cancer development, chemoresistance, and anti-tumor immunity is currently unknown. The central hypothesis is that PP4 inhibition will sensitize OC cells to chemotherapy-mediated immunogenicity leading to enhanced anti- tumor immunity, and increased response to immune checkpoint blockade. The rationale for the proposed research is that understanding of the how the immune response is activated in reaction to deficiencies in PP4- mediated DNA damage repair has the potential to translate into new therapeutic strategies that will benefit those with ovarian cancer. This hypothesis will be tested by pursuing the following two specific aims: 1) Determine the role of the PP4 complex in the immunogenicity of OC; and 2) Determine the role of PP4 in tumor-infiltrating lymphocyte recruitment, function, and response to immunotherapy. In Aim 1 the effect of PP4 knockout on chemotherapy-induced immunogenicity will be assessed using mechanistic studies of genomic instability, antigen presentation, and immunogenic cell death. Under the second Aim the effect of PP4 deficiency combined with PD-1 inhibition and chemotherapy will be evaluated in organoid cultures of primary human ovarian cancer and in two immunocompetent mouse models of ovarian cancer. Mechanisms of inflammatory signaling will be investigated. The research proposed in this application is innovative because it represents a new theoretical concept by shifting the focus on PP4 function to its role in anti-tumor immunity. The proposed research is significant because it is predicted to advance and expand our understanding of the importance of how DNA damage repair resolution contributes to anti-tumor immunity and response to immunotherapy. Ultimately, such knowledge has the potential to inform the development of new therapies benefiting many types of cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $457,776 )
2025	2025	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	000	3	7/23/2025	NON-COMPETING CONTINUATION	$457,776
														Subtotal = $457,776

Issue Date FY: 2024 ( Subtotal = $434,357 )
2024	2024	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	000	2	7/29/2024	NON-COMPETING CONTINUATION	$434,357
														Subtotal = $434,357

Issue Date FY: 2023 ( Subtotal = $510,892 )
2023	2023	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	000	1	8/3/2023	NEW	$510,892
														Subtotal = $510,892

Grand Total All Awards = $1,403,025

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting PP4 to improve ovarian cancer response to immunotherapy

Award Number: R37CA276047

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/03/2023

PERIOD OF PERFORMANCE END DATE: 07/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer